Andrew Perlman

Andy has had a notable career in drug development, most significantly at Genentech from 1988 to 1993, whereas Senior Director of Clinical Research played a key role in the development, FDA approval, and marketing of human growth hormone (hGH, Nutropin). After Genentech, Andy was one of the first hires at Tularik, a new drug discovery company, where he served as Vice President and then Executive Vice President until 2004. While at Tularik, Andy's responsibilities included participating in the selection of promising targets for new drugs. In addition, he was responsible for clinical trial design and implementation, filing Tularik's first IND, and initiating the relevant clinical trials. H played an active role in Tularik's acquisition by Amgen in 2004 for $1.3 billion.

Following the acquisition of Tularik, Andy was the founder and CEO of Innate Immune Inc., an early-stage biotech company focusing on therapies for asthma and autoimmune diseases. Andy has a B.S. from MIT, an M.D., and a Ph.D. in physiology from New York University (NYU). He did his Ph.D. research in the laboratory of Nobel laureate Professor Eric Kandel. He received postgraduate clinical training at Stanford School of Medicine and NYU. From 1984 to 1987 he was an assistant professor at Stanford University where he did clinical work, teaching, and research on hypertension.